Literature DB >> 24007817

Dexmedetomidine protects against ischemia-reperfusion injury in rat skeletal muscle.

Xu Dong1, Qunzhi Xing, Yu Li, Xuechang Han, Lixia Sun.   

Abstract

BACKGROUND: Dexmedetomidine (DEX) has been shown to decrease ischemia-reperfusion (I/R) injury in kidney and brain tissues. In this study, the effects of DEX were evaluated in skeletal muscle during I/R injury.
MATERIALS AND METHODS: Animals were divided into four groups: sham-operated (sham group), saline + I/R, DEX + I/R, and α-tocopherol + I/R groups. Hind limb ischemia was induced by clamping the common femoral artery and vein. After 4 h of ischemia, the clamp was removed and the animals underwent 2 h of reperfusion. Animals in the drug treatment group received DEX or α-tocopherol by intraperitoneal injection 1 h before reperfusion. We measured plasma concentrations of interleukin 1β and tumor necrosis factor α levels using an enzyme-linked immunosorbent assay. The right gastrocnemius muscle was harvested and immediately stored at -80°C for the assessment of superoxide dismutase (SOD) and catalase (CAT) activities as well as glutathione (GSH), malondialdehyde (MDA), and protein oxidation (PO) levels. DEX (25 μg/kg) and normal saline (10 mL/kg) were administered by intraperitoneal injection 1 h before reperfusion.
RESULTS: Plasma tumor necrosis factor α or interleukin 1β levels increased significantly in the I/R group (P < 0.01 compared with sham group) and decreased significantly in the DEX group (P < 0.01 compared with I/R group). Muscle tissues of the I/R group had significantly decreased SOD, GSH, and CAT activities and increased levels of MDA and PO content compared with the sham group. The activity of antioxidant enzymes in the DEX + I/R group was greatly elevated compared with that in the I/R group (SOD, 1.068 ± 0.120 versus 0.576 ± 0.072 U/mg protein; GSH, 2.436 ± 0.144 versus 1.128 ± 0.132 μmol/g; and CAT, 69.240 ± 6.456 versus 31.884 ± 6.312 U/mg protein; P < 0.01), whereas the levels of MDA and PO content were clearly reduced (23.268 ± 3.708 versus 53.604 ± 5.972 nmol/g protein and 1.908 ± 0.192 versus 5.208 ± 0.612 nmol/mg protein, respectively; P < 0.01). Moreover, DEX exhibited more potent antioxidant activity than vitamin E in the skeletal muscle I/R.
CONCLUSIONS: We found that DEX exhibits protective effects against skeletal muscle I/R injury. These results underscore the necessity of human studies with DEX to determine if it is beneficial for preventing skeletal muscle I/R injury.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dexmedetomidine; Ischemia–reperfusion injury; Reactive oxygen species; Skeletal muscle

Mesh:

Substances:

Year:  2013        PMID: 24007817     DOI: 10.1016/j.jss.2013.07.052

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  22 in total

1.  Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Authors:  Gabriela Calhoun; Li Wang; Luis E F Almeida; Nicholas Kenyon; Nina Afsar; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  Eur J Pharmacol       Date:  2015-02-25       Impact factor: 4.432

2.  Dexmedetomidine alleviates the spinal cord ischemia-reperfusion injury through blocking mast cell degranulation.

Authors:  Jun Ma; Xiao-Long Zhang; Cheng-Yu Wang; Zhi Lin; Jie-Ru Tao; Hua-Cheng Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  The Preventive Effect of Dexmedetomidine Against Postoperative Intra-abdominal Adhesions in Rats.

Authors:  Serdar Kuru; Osman Bahadir Bozkirli; Aziz Mutlu Barlas; Mehmet Esat Duymus; Mehmet Senes; Nihat Yumusak; Cevdet Yilmaz; Kemal Kismet
Journal:  Int Surg       Date:  2015-01

4.  Lipoxin A4 pretreatment mitigates skeletal muscle ischemia-reperfusion injury in rats.

Authors:  Haiyang Zong; Xinghui Li; Haodong Lin; Chunlin Hou; Fenfen Ma
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

5.  Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.

Authors:  Kathy A Sheehy; Julia C Finkel; Deepika S Darbari; Michael F Guerrera; Zenaide M N Quezado
Journal:  Pain Pract       Date:  2015-07-23       Impact factor: 3.183

6.  Dexmedetomidine attenuates isoflurane-induced cognitive impairment through antioxidant, anti-inflammatory and anti-apoptosis in aging rat.

Authors:  Xiaoning Wang; Binjiang Zhao; Xue Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  Simvastatin inhibits inflammation in ischemia-reperfusion injury.

Authors:  Yilin Zhao; Qingzhao Feng; Zhengjie Huang; Wenpeng Li; Baisheng Chen; Long Jiang; Binglin Wu; Weiji Ding; Gang Xu; Heng Pan; Wei Wei; Weiyuan Luo; Qi Luo
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

8.  Dexmedetomidine Analgesia Effects in Patients Undergoing Dental Implant Surgery and Its Impact on Postoperative Inflammatory and Oxidative Stress.

Authors:  Sisi Li; Yang Yang; Cong Yu; Ying Yao; Yujia Wu; Lian Qian; Chi Wai Cheung
Journal:  Oxid Med Cell Longev       Date:  2015-06-15       Impact factor: 6.543

9.  Dietary Intake of Vitamin E and Fats Associated with Sarcopenia in Community-Dwelling Older Japanese People: A Cross-Sectional Study from the Fifth Survey of the ROAD Study.

Authors:  Yuta Otsuka; Toshiko Iidaka; Chiaki Horii; Shigeyuki Muraki; Hiroyuki Oka; Kozo Nakamura; Takayuki Izumo; Tomohiro Rogi; Hiroshi Shibata; Sakae Tanaka; Noriko Yoshimura
Journal:  Nutrients       Date:  2021-05-20       Impact factor: 5.717

10.  Low Serum Vitamin E Level Associated with Low Hand Grip Strength in Community-Dwelling Adults: Korean National Health and Nutrition Examination Survey (KNHANES VII) 2016-2018.

Authors:  Yongjae Kim; Sungjae Shin; Namki Hong; Yumie Rhee
Journal:  Nutrients       Date:  2021-05-11       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.